Late-stage biotechnology company Akari Therapeutics, Plc (Nasdaq: AKTX) has announced the appointment of Samir R. Patel, M.D. to its Board of Directors. Dr. Patel, an experienced life sciences entrepreneur and long-time investor in Akari, brings a wealth of knowledge and a successful track record with startup companies. Akari Chairman Ray Prudo, M.D. expressed his pleasure in having Dr. Patel join the Board of Directors during this crucial phase of the company’s development. Dr. Patel, who founded PranaBio Investments, LLC and is currently a consultant to GE Global Research, stated that he is honored to have the opportunity to help realize the potential of Akari’s lead asset, nomacopan, on behalf of patients and shareholders.
Dr. Patel’s extensive experience in the life sciences industry includes co-founding Digital Therapeutics, LLC and SPEC Pharma, LLC, as well as holding multiple roles in Medical Affairs with Centocor, Inc. He is a graduate of the Medical College of Ohio and completed his medical training at the University of New Mexico School of Medicine Affiliated Hospitals. Akari Therapeutics is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, nomacopan, is currently being investigated in a Phase 3 clinical trial for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).
